Bristol-Myers Squibb

Últimas notícias

Manchetes no idioma original da fonte.

• What Does Bristol Myers Squibb (BMY) Gain From Its Broader Heart Drug Approval? (abre em uma nova aba)

  Simply Wall Street · 2 de out. de 2026

• AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap (abre em uma nova aba)

  NAI500 · 2 de out. de 2026

• AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? (abre em uma nova aba)

  fool.com · 1 de out. de 2026

• Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day (abre em uma nova aba)

  MarketWatch · 1 de out. de 2026

• Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale (abre em uma nova aba)

  fool.com · 1 de out. de 2026

• Bristol Myers Squibb (BMY) Boosts Champions in Care Initiative w (abre em uma nova aba)

  GuruFocus · 1 de out. de 2026

• Bristol Myers Squibb Deepens Commitment To Healthcare Professionals Through Champions In Care Movement (abre em uma nova aba)

  TradingView · 1 de out. de 2026

• Bristol Myers Squibb secures expanded US approval for Camzyos (abre em uma nova aba)

  Yahoo · 1 de out. de 2026

• What You Could Reuse From Bristol Myers Squibb's 46% Gain (abre em uma nova aba)

  Simply Wall Street · 30 de set. de 2026

• Bristol Myers trial revisions shake confidence in new class of fibrosis drugs (abre em uma nova aba)

  BioPharma Dive · 30 de set. de 2026

• Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric (abre em uma nova aba)

  Yahoo Finance · 30 de set. de 2026

• Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know (abre em uma nova aba)

  Yahoo Finance · 30 de set. de 2026

• How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors (abre em uma nova aba)

  Yahoo Finance · 30 de set. de 2026

• Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? (abre em uma nova aba)

  fool.com · 29 de set. de 2026

• Potential liver safety issue seen in phase 3 trial for Bristol's admilparant (abre em uma nova aba)

  Seeking Alpha · 29 de set. de 2026

• Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial (abre em uma nova aba)

  Yahoo Finance · 29 de set. de 2026

• Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data? (abre em uma nova aba)

  Simply Wall Street · 29 de set. de 2026

• 3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation (abre em uma nova aba)

  fool.com · 29 de set. de 2026

• Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers (abre em uma nova aba)

  Yahoo Finance · 29 de set. de 2026

• Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook? (abre em uma nova aba)

  Yahoo Finance · 29 de set. de 2026

• Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue? (abre em uma nova aba)

  Yahoo Finance · 28 de set. de 2026

• Bristol Myers Squibb Co. stock outperforms competitors on strong trading day (abre em uma nova aba)

  MarketWatch · 28 de set. de 2026

• Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa (abre em uma nova aba)

  Yahoo Finance · 28 de set. de 2026

• Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? (abre em uma nova aba)

  Yahoo Finance · 27 de set. de 2026

• Exploring New CAR-T Approaches for Relapsed Multiple Myeloma – Bristol Myers Squibb (abre em uma nova aba)

  Oncodaily · 25 de set. de 2026

• Rx Rundown: Lilly, Bristol Myers Squibb, Johnson & Johnson and more (abre em uma nova aba)

  Medical Marketing and Media · 25 de set. de 2026

• What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders (abre em uma nova aba)

  Simply Wall Street · 25 de set. de 2026

• Bristol Myers Squibb’s Zenbexus shows improved response rates (abre em uma nova aba)

  Investing.com · 25 de set. de 2026

• Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma (abre em uma nova aba)

  Business Wire · 25 de set. de 2026

• Bristol Myers Squibb (NYSE:BMY) Upgraded to Strong-Buy at Zacks Research (abre em uma nova aba)

  MarketBeat · 25 de set. de 2026